Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:defunct |
2010
|
| gptkbp:focus |
specialty pharmaceuticals
|
| gptkbp:foundedBy |
gptkb:Eugene_Melnyk
|
| gptkbp:foundedYear |
1991
|
| gptkbp:headquartersLocation |
Mississauga, Ontario, Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biovail
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Eugene_Melnyk
gptkb:Douglas_Squires gptkb:Bill_Wells |
| gptkbp:mergedInto |
gptkb:Valeant_Pharmaceuticals
2010 |
| gptkbp:notableEvent |
class action lawsuits
accounting scandal SEC investigation in 2003 |
| gptkbp:notableProduct |
gptkb:Wellbutrin_XL
gptkb:Cardizem_LA |
| gptkbp:successor |
gptkb:Valeant_Pharmaceuticals_International,_Inc.
|
| gptkbp:tradedOn |
gptkb:NYSE:_BVF
gptkb:TSX:_BVF |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|